Related by context. All words. (Click for frequent words.) 75 secondary efficacy endpoints 71 prespecified 71 Primary endpoints 70 noninferiority 70 CR nPR 70 Kaplan Meier analysis 69 secondary endpoint 69 morphometric vertebral fractures 69 Secondary efficacy endpoints 69 RE LY ® 69 secondary efficacy endpoint 69 attain statistical significance 68 mRCC 68 pharmacokinetic PK 68 subgroup analyzes 68 STRIDE PD 68 virologic response 68 pCR 68 efficacy evaluable 68 evaluable 68 relapsed MM 68 achieved statistical significance 67 efficacy endpoint 67 KRAS status 67 VADT 67 HER2 expression 67 composite endpoint 67 dose cohort 67 dosing cohort 67 PRIMO CABG 67 eplerenone 67 SIMPADICO 67 pharmacodynamic PD 67 HSCT 67 evaluable patients 67 metastatic HRPC 67 complete cytogenetic response 67 genotypic resistance 66 placebo controlled randomized 66 virological response 66 nonrandomized 66 microbiologically evaluable 66 lymphocytosis 66 biochemical recurrence 66 galiximab 66 patients evaluable 66 NATRECOR R 66 active comparator 66 prognostic variables 66 multivariate Cox 66 prospectively stratified 66 pharmacokinetics PK 66 liver transplant recipients 66 low dose cytarabine 66 nab paclitaxel 66 undetectable HBV DNA 66 virologic failure 66 multicenter randomized controlled 66 remission CR 66 DAS# CRP 66 viral kinetics 66 mCRC patients 66 prespecified secondary 66 median PFS 66 placebo controlled clinical 66 XIENCE V PROMUS Stent 66 Subgroup analysis 66 recurrent glioblastoma multiforme 66 clinically evaluable 66 undergoing coronary angiography 66 multivariate analyzes 66 evaluable subjects 66 SYMMETRY trial 66 efficacy endpoints 66 timepoint 66 histologically confirmed 66 neoadjuvant chemotherapy 66 HCV RESPOND 2 66 univariate analysis 66 definite stent thrombosis 66 statistical significance p 66 APPRAISE 66 MGd 66 subanalysis 65 MADIT II 65 antibody titer 65 TAXUS V 65 sustained virological response 65 BRIM3 65 response CCyR 65 postintervention 65 HCV SPRINT 65 pharmacokinetic parameters 65 CRp 65 neoadjuvant 65 CALGB 65 Hb A1C 65 progression TTP 65 surrogate endpoint 65 primary efficacy endpoint 65 riociguat 65 recurrent GBM 65 adenoma recurrence 65 phase Ib 65 satraplatin Phase 65 heavily pretreated 65 prospective randomized placebo 65 EURIDIS 65 estramustine 65 corticosteroid dose 65 comparator arm 65 HIV HCV coinfected 65 mg kg dose 65 antiretroviral naïve 65 biochemical relapse 65 nondiabetic patients 65 ANCHOR trial 65 Secondary endpoints 65 Secondary endpoints include 65 HBeAg seroconversion 65 randomized blinded 65 HORIZONS AMI trial 65 canakinumab 65 trials RCTs 65 CIMZIA TM 65 viral kinetic 65 Kaplan Meier curve 65 CCyR 65 darunavir ritonavir 65 locoregional 65 CIMZIA ™ 65 pain palliation 65 MEND CABG II 65 Ceplene/IL-2 65 p# biomarker 65 prospective multicenter randomized 65 Randomized Evaluation 65 liver histology 65 Secondary endpoints included 64 desvenlafaxine succinate 64 Response Evaluation Criteria 64 Kaplan Meier method 64 oral FTY# 64 specific antigen PSA 64 ACCORD Lipid 64 tumor histology 64 mITT 64 metastatic GIST 64 Non inferiority 64 oblimersen 64 DMARD 64 noninferior 64 imatinib therapy 64 PREZISTA r 64 neurologic progression 64 IL#B 64 multicenter randomized placebo controlled 64 Phase Ib study 64 HOMA IR 64 PCI ExTRACT TIMI 64 microalbuminuria 64 retrospective cohort 64 Solid Tumors RECIST 64 cancer mCRC 64 Doxil ® 64 mcg dose 64 MAGE A3 ASCI 64 prostate cancer PCa 64 PSA nadir 64 CANCIDAS 64 HBeAg 64 GAMMAGARD 64 serum urate 64 nonfatal MI 64 virologic 64 histological subtype 64 advanced neoplasia 64 placebo controlled clinical trials 64 % CI #.#-#.# [003] 64 RECIST criteria 64 HIV RNA 64 pharmacodynamic endpoints 64 fosbretabulin 64 cilostazol 64 secondary endpoints 64 NovoTTF 64 endoscopic remission 64 primary endpoint 64 serum HCV RNA 64 phase IIb study 64 BCIRG 64 DAS# remission 64 androgen suppression 64 KRAS mutations occur 64 HBeAg negative patients 64 clinically meaningful improvement 64 ToGA 64 baseline HbA1c 64 randomized Phase 2b 64 multicentre randomized 64 CTEPH 64 SCr 64 TRITON TIMI 64 rALLy trial 64 APTIVUS r 64 ongoing Phase 1b 64 ritonavir boosted 64 ischemic cardiomyopathy 64 Val HeFT 64 clinical endpoints 64 adjuvant therapy 64 teriflunomide 64 F FDG PET 63 univariate 63 crizotinib PF # 63 PSADT 63 PRIMO CABG2 63 BRIM2 63 AVOREN 63 phase IIb clinical 63 Kaplan Meier 63 CC genotype 63 maximally tolerated dose 63 CIMZIA TM certolizumab pegol 63 dosage regimens 63 antiangiogenic therapy 63 androgen deprivation 63 locoregional recurrence 63 covariate 63 posaconazole 63 FOLPI 63 mg/m2 dose 63 cTnI 63 LV dysfunction 63 INCB# [001] 63 NYHA functional class 63 dose escalation phase 63 bosentan 63 symptomatic VTE 63 Index CDAI 63 prospective multicenter 63 response pCR 63 MEND CABG 63 randomized Phase III 63 paricalcitol 63 exploratory endpoints 63 mcg albinterferon alfa 2b 63 MERLIN TIMI 63 pegylated interferon alfa 2b 63 multivariable analysis 63 plasma pharmacokinetics 63 peg interferon 63 receptor tyrosine kinase inhibitor 63 glycated hemoglobin levels 63 #mg dose [002] 63 RE LY 63 FOLFIRI 63 HBeAg positive patients 63 NNRTI resistance 63 prostate cancer CaP 63 univariate analyzes 63 timepoints 63 β blockers 63 RECIST Response Evaluation Criteria 63 mITT population 63 paclitaxel eluting stents 63 SVR# 63 HbA1c levels 63 Cloretazine 63 mapatumumab 63 vismodegib 63 serum phosphorous 63 complete cytogenetic 63 K ras mutations 63 PITX2 methylation 63 EDEMA3 trial 63 R# #mg BID 63 tumor recurrence 63 carotid intima media 63 ROCKET AF 63 PROactive study 63 postoperative chemotherapy 63 Baseline characteristics 63 pertuzumab 63 rapid virologic response 63 BENICAR HCT 63 masked placebo controlled 63 everolimus eluting stents 63 sustained virologic response 63 confirmatory clinical 63 irbesartan 63 primary endpoints 63 pharmacodynamics PD 63 ACUITY trial 63 hsCRP levels 63 Free Survival PFS 63 free survival PFS 63 DAPT 63 BEXXAR Therapeutic Regimen 63 advanced adenomas 63 Folfox 63 QTc prolongation 63 placebo controlled Phase III 63 platelet reactivity 63 ascending doses 63 florbetaben 63 periprocedural MI 63 PERSEUS 63 dexpramipexole 63 elotuzumab 63 meta regression 63 PASI scores 63 docetaxel pretreated 63 plus dexamethasone 63 Phase Ib clinical 63 EFAPROXYN 63 non inferiority 63 achieved sustained virological 63 PITX2 63 angiographic outcomes 62 goserelin 62 FDG PET scans 62 conditional logistic regression 62 achieved ACR# 62 tipranavir r 62 certolizumab 62 PEG IFN 62 neoadjuvant therapy 62 serum calcium levels 62 locoregional disease 62 baseline LDH 62 assessing T DM1 62 AVADO 62 scintigraphic 62 Xanafide 62 EMPHASIS HF trial 62 landmark ATHENA 62 randomized multicenter trial 62 methotrexate monotherapy 62 serum creatinine levels 62 neutrophil counts 62 CARE HF 62 carotid IMT 62 prognostic indicators 62 TAXUS IV 62 postoperative complication 62 T#I [002] 62 statistically significant p = 62 colorectal adenoma 62 Flu Cy 62 chemoradiotherapy 62 randomized multicenter 62 pharmacodynamic markers 62 ADAGIO study 62 NIHSS score 62 ipsilateral stroke 62 insulin detemir 62 metabolic parameters 62 sUA 62 underwent resection 62 EGFR TKI 62 CIN2 + 62 FOLFOX4 62 pharmacodynamic 62 XIENCE V demonstrated 62 Carotid Revascularization Endarterectomy vs. 62 Thrombolysis 62 sipuleucel T 62 metastatic CRC 62 CHAMPION PCI 62 visceral metastases 62 TACE 62 subcutaneous PRO 62 histologic subtype 62 hemoglobin A1c levels 62 oral rivaroxaban 62 DLTs 62 distant metastasis 62 tipranavir ritonavir 62 serum concentrations 62 pharmacodynamic effects 62 TMC# C# 62 multivariate logistic regression 62 prostate carcinoma 62 HGPIN 62 lymphadenectomy 62 ertapenem 62 adjuvant tamoxifen 62 multicenter placebo controlled 62 Phase Ib II 62 prucalopride 62 dose cohorts 62 #mg/m# [002] 62 Pharmacokinetic 62 non squamous NSCLC 62 prospective multicentre 62 sirolimus eluting stents 62 chlorambucil 62 leukocyte count 62 serum testosterone 62 virological failure 62 melphalan prednisone 62 ADAS Cog 62 % CI #.#-#.# [007] 62 virologic responses 62 Phase 2b randomized 62 velafermin 62 thromboembolic events 62 ATACAND 62 aminotransferase levels 62 NCT# ClinicalTrials.gov 62 mg/m2 cohort 62 dosing cohorts 62 tumor progression TTP 62 HbA1C levels 62 histologic 62 IFN α 62 posttransplant 62 HBsAg 62 fallopian tube cancers 62 Crohn Disease Activity 62 4mg/kg 62 abacavir lamivudine 62 5-fluorouracil/leucovorin 62 fluvastatin 62 tolerated dose MTD 62 neoadjuvant treatment 62 preoperative chemotherapy 62 CR CRu 62 logistic regression models 62 peginterferon alfa 2b 62 pretest probability 62 intraobserver 62 alvespimycin 62 partial remissions 62 recurrent GBM patients 62 HBeAg negative 62 ADCS CGIC 62 trastuzumab emtansine T DM1 62 MELD scores 62 OPT CHF 62 adjunctive placebo 62 p = #.# [003] 62 intravesical therapy 62 preintervention 62 statistically significant efficacy 62 NSABP 62 cisplatin vinorelbine 62 Xelox 62 achieved CCyR 62 Pharmacokinetic parameters 62 stage IIIB 62 relapsed AML 62 confirmed CCyR 62 methotrexate therapy 62 tumor necrosis 62 intact parathyroid hormone 62 HAQ DI 62 randomized Phase IIb 62 CAMMS# 62 nonmetastatic prostate cancer 62 primary efficacy endpoints 62 dose dose escalation 62 dose clopidogrel 62 undetectable HCV RNA 62 ACTEMRA TM 62 specified primary endpoint 62 mutated K ras 62 ribavirin RBV 62 T2 lesions 62 clodronate 62 ARCOXIA 62 6MWD 62 pretransplant 62 Solid Tumors criteria 62 heavily pretreated patients 62 FDG PET 62 observational cohort 62 ruboxistaurin 61 recurrent VTE 61 NMIBC 61 PCWP 61 logistic regression analysis 61 pharmacokinetic PK profile 61 mg BID dose 61 rhGH 61 randomized #:# 61 placebo controlled trials 61 vidofludimus 61 BARI 2D 61 A1c levels 61 TOP2A 61 ADAS cog 61 haematologic 61 KRAS mutation 61 Subgroup analyzes 61 Phase 1a clinical 61 pegylated liposomal doxorubicin PLD 61 blind placebo 61 anti leukemic 61 microbiological eradication 61 sunitinib 61 adjuvant GIST 61 protease inhibitor PI 61 HYVET 61 atazanavir ritonavir 61 ARB telmisartan 61 hemodynamically significant 61 titrated glipizide 61 ECOG 61 Phase 2a trial 61 serum phosphate levels 61 papillary renal cell carcinoma 61 tipranavir 61 cytogenetic response 61 APTIMA HPV 61 covariates 61 eculizumab therapy 61 salmeterol fluticasone 61 Phase 2b study 61 intima media thickness 61 octreotide LAR 61 pomalidomide 61 rALLy 61 oocytes retrieved 61 ACR# response 61 treatment naive genotype 61 pegylated liposomal doxorubicin 61 glycosylated hemoglobin levels 61 phase IIb trial 61 PCa 61 double blinded placebo 61 substudy 61 COPERNICUS 61 rFVIIa 61 advanced adenoma 61 curative resection 61 Lp PLA 2 61 pharmacokinetic characteristics 61 resected pancreatic cancer 61 null responder HCV 61 HbA 1c 61 logistic regression model 61 hip BMD 61 ispinesib administered 61 serum HBV DNA 61 atheroma volume 61 lispro 61 tanespimycin 61 HIV uninfected 61 MMSE score 61 BOLDER II 61 EVEREST II 61 apremilast 61 PROTECT II 61 T2DM 61 analgesic efficacy 61 lipid lowering agents 61 postoperative AF 61 echocardiographic parameters 61 COU AA 61 mesalamine granules 61 NSABP C 61 coronary stenosis 61 double blinded randomized 61 peginterferon 61 neratinib 61 troponin T 61 cardiac dysfunction 61 clinically localized prostate 61 Proellex TM 61 stage IIIb IV 61 LEXIVA r 61 multicenter multinational 61 pancreatic adenocarcinoma 61 mycophenolate mofetil 61 prospective observational 61 GFT# 61 #mg BID [003] 61 gemcitabine carboplatin 61 #F FDG PET 61 μmol L 61 APTIVUS 61 seroprotection 61 distant metastases 61 azacitidine 61 NATRECOR ® 61 ELACYT 61 venlafaxine XR 61 posttreatment 61 randomized controlled trials RCTs 61 TLUS 61 clinico pathological 61 idraparinux 61 alteplase 61 IMPACT DCM 61 plasma uric acid 61 CLORETAZINE TM VNP#M 61 sorafenib Nexavar ® 61 β blocker 61 boosted protease inhibitor 61 RRMS patients 61 FDA defined valvulopathy 61 axillary lymph node 61 #mg QD [001] 61 antioxidant supplementation 61 taxane resistant 61 ENDEAVOR III 61 R0 resection 61 carboplatin paclitaxel 61 blinded randomized placebo controlled 61 serum lipid levels 61 nodular partial response 61 EDSS score 61 glufosfamide 61 CCX# 61 PNH patients 61 serum phosphorus 61 recurrent malignant glioma 61 Prostate Cancer Prevention 61 liver metastases 61 evaluating tivozanib 61 MoxDuo TM IR 61 atherogenic dyslipidemia 61 fluoropyrimidine 61 IPAH 61 invasive aspergillosis 61 hematopoietic cancers 61 Phase III randomized controlled 61 acute GvHD 61 clevidipine 61 chemosensitivity 61 adecatumumab 61 estimated glomerular filtration 61 concurrent chemoradiation 61 biliary tract cancer 61 NSABP B 61 TDF FTC 61 etiologic 61 SYNTAX trial 61 Bezielle 61 ZACTIMA 61 fibrinolytic therapy 61 metastatic renal cell carcinoma 61 sleeve lobectomy 61 5-FU/LV 61 tirofiban 61 retinal thickness 61 nonresponders 61 NOX E# 61 tolvaptan 61 PLCO 61 nucleoside naive patients 61 ExTRACT TIMI 61 cEVR 61 serum urate levels 61 unresectable HCC 61 NPH insulin 61 doxorubicin docetaxel 61 OADs 61 phase IIa clinical 61 clinically meaningful differences 61 Phase 1a 61 docetaxel chemotherapy 61 FOLFOX6 61 VcMP 61 Tumor Response 61 QTc 61 Virologic 61 glycosylated hemoglobin HbA1c 61 TAXUS Stent 61 NNT = 61 limiting toxicity 61 daily subcutaneous injections 61 periprocedural 61 axitinib 61 SPIRIT FIRST 61 CLIRS 61 Phase IIIb clinical 61 gefitinib Iressa 61 Amrubicin 61 peginterferon alfa 61 ICD implantation 61 dose escalation Phase 61 pramlintide metreleptin combination 61 lumbar spine BMD 61 Meta analyzes 61 elacytarabine 61 baseline FEV 61 eribulin mesylate 61 preoperative PSA 61 atherothrombotic disease 61 dose dexamethasone 61 serum aminotransferase levels 61 blind randomized controlled 61 GIK infusion 61 dalteparin 61 aminotransferase ALT 61 prostate cancer CRPC 61 rosuvastatin #mg 61 antiretroviral naive 61 NIH CPSI 61 prospectively randomized 61 GnRH agonist 61 binary restenosis 61 Enzastaurin 61 HGS ETR2 61 SSc 61 Scale EDSS 61 GOUT 61 MetMAb 61 CA4P 61 HER2 positive metastatic breast 61 relapsed MCL 61 nonmetastatic 61 ibandronate 61 refractory prostate cancer 61 urinary N telopeptide 61 randomized multicentre 61 ABC/3TC 61 CHAMPION PLATFORM 61 lactate dehydrogenase LDH 61 safety tolerability pharmacokinetic 60 demonstrated clinically meaningful 60 SCD HeFT 60 lymph node involvement 60 pharmacodynamic parameters 60 IOP lowering 60 Candesartan 60 RESIST studies 60 ug dose 60 SORT OUT III 60 metachronous 60 metastatic malignant melanoma 60 flutamide 60 glomerular filtration 60 randomized multicenter Phase III 60 thyrotropin levels 60 salmeterol fluticasone propionate 60 lopinavir r 60 HbA 1c levels 60 serum PSA 60 ANCOVA 60 disease progression TTP 60 antiangiogenic agent 60 mg BID 60 Apoptone 60 HeFT 60 avosentan 60 Randomised 60 LUX Lung 60 liposomal doxorubicin 60 QTcF 60 XELOX 60 prospective randomized controlled 60 Stage IIIb 60 KRAS mutations 60 YERVOY 60 MADIT CRT trial 60 Kaplan Meier estimates 60 BR.# 60 NEO3 60 subclinical hypothyroidism 60 Dose escalation 60 ONTARGET 60 VELCADE melphalan 60 colorectal liver metastases 60 Multicenter Automatic Defibrillator Implantation 60 RG# [001] 60 antidepressant efficacy 60 lintuzumab 60 cTnT levels 60 micafungin 60 paclitaxel carboplatin 60 Edge STudy 60 unfractionated heparin UFH 60 CrCl 60 eptifibatide 60 pharmacokinetic PK study 60 NAbs 60 serum IGF 60 prospective randomized multicenter 60 SNP rs# [002] 60 Tarceva TM 60 CK # plasma concentrations 60 LVEF 60 platinum refractory 60 Montgomery Åsberg Depression 60 tumor xenograft models 60 serum uric acid 60 calculated creatinine clearance 60 placebo controlled Phase 60 non squamous histology 60 intravenous dosing 60 cytoreductive nephrectomy 60 BRAF mutation 60 pharmacodynamic properties 60 8mg/kg 60 surrogate markers 60 candesartan cilexetil 60 serum biomarkers 60 elevated ALT 60 ICD therapy 60 FOLFOX 60 cobiprostone 60 Telintra 60 HER2 overexpression 60 Virulizin ® 60 adverse cytogenetics 60 null responder 60 specified secondary endpoints 60 phase IIa 60 CVD mortality 60 Brief Psychiatric 60 dacarbazine chemotherapy 60 multicenter Phase II 60 anti JCV antibodies 60 normotensive 60 sitaxsentan 60 histologically proven 60 randomizing patients 60 Randomized trials 60 UPLYSO 60 mcg BID 60 paroxysmal AF 60 Echocardiographic 60 Prostate AdenoCarcinoma Treatment 60 ancrod 60 alanine aminotransferase ALT 60 hyperoxaluria 60 prognostic factors 60 antipsychotic efficacy 60 HbA1C 60 oral ridaforolimus 60 HCV replicon 60 genotypic 60 cytogenic 60 perioperative complications 60 T1DM 60 zotarolimus eluting stent 60 statistically significant correlations 60 Univariate analysis 60 coinfected patients 60 revascularizations 60 Allovectin 7 ® 60 IFN beta 60 recurrent venous thromboembolism 60 hematological parameters 60 histopathological 60 EGFR HER2 60 EchoCRT 60 enoximone 60 adjuvant therapies 60 null responders 60 Aflibercept 60 longitudinal cohort study 60 briakinumab 60 macroalbuminuria 60 budesonide foam 60 unresectable stage 60 nicardipine 60 clinicopathological features 60 TAXUS Express Stent 60 plus prednisone 60 retrospective observational study 60 vertebral fracture 60 IFN alfa 60 hepatic fibrosis 60 mCRPC 60 RSD# oral 60 metastatic castration resistant 60 kidney allograft 60 EDEMA3 60 MADRS score 60 CLL SLL 60 tapentadol ER 60 systemic ALCL 60 ALLHAT 60 favorable pharmacokinetic profile 60 Viral load 60 metastatic RCC 60 thyroglobulin 60 NO# [002] 60 HBeAg positive 60 Randomized controlled 60 fosamprenavir 60 iniparib 60 PSN# [002] 60 CALGB # [002] 60 randomized discontinuation trial 60 #mg/day [001] 60 trastuzumab Herceptin ® 60 Pemetrexed 60 Ranolazine 60 NHANES III 60 anthracycline taxane 60 PIX# [002] 60 SLNB 60 Onrigin 60 aldosterone antagonist 60 reinfarction 60 vicriviroc 60 lipid lowering therapy 60 dacarbazine 60 Phase III randomized 60 edifoligide 60 saline placebo 60 ovarian carcinoma 60 undergone radical prostatectomy 60 chest radiographs 60 lymph node metastasis 60 lanthanum carbonate 60 plasma folate 60 TMC# r 60 recurrent ischemia 60 sunitinib malate 60 antitumor effect 60 metformin monotherapy 60 Androxal TM 60 operable breast cancer 60 keloid scarring 60 nodal metastasis 60 opioid naïve 60 AIM HIGH 60 infarct size 60 Montgomery Asberg Depression 60 Pharmacokinetic PK 60 resectable pancreatic cancer 60 gefitinib 60 postmenopausal osteoporotic women 60 TIMP 1 60 multivariable Cox 60 pT3 60 KRAS wild 60 systolic dysfunction 60 achieve sustained virologic 60 IU ml 60 ACZ# 60 underwent surgical resection 60 adalimumab 60 Randomized clinical trials 60 relapsing remitting MS RRMS 60 spirometric 60 hepatitis C genotype 60 FDG-PET/CT 60 p = .# [002] 60 EBRT 60 antiarrhythmic drug 60 histopathologic 60 reintervention 60 postoperative mortality 60 mL/min/#.# m 2 60 placebo controlled studies 60 refractory NSCLC 60 mg ustekinumab 60 Motesanib 60 GVAX 60 oxycodone CR 60 lipid lowering therapies 60 APTIVUS R 60 follicular NHL 60 AVERROES 60 iloprost 60 mcg kg 60 lumiliximab 60 budesonide MMX 60 Kaplan Meier curves 60 enzastaurin 60 #Gy 60 CMV disease 60 -#.# log# 60 Vectibix monotherapy 60 cobicistat 60 hemoglobin A1c HbA1c 60 death reinfarction 60 OvaRex MAb 60 Octreolin 60 Phase 1b 60 #mg BID [001] 60 annualized relapse 60 IIIa inhibitor 60 EUS FNA 60 olmesartan 60 CLIRS trial 60 BCG refractory 60 Prostate Lung Colorectal 60 HIV coinfected 60 HGS ETR1 60 tolerability pharmacokinetics 60 liver metastasis 60 nilotinib 60 CD4 + cell 60 mcg QD 60 placebo controlled dose escalation 60 antiretroviral regimen 60 Events MACE 60 tumor shrinkage 60 huN# DM1 60 ejection fractions